These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 6541918)
1. Drug-protein interactions. Inhibition of the action of levamisole on human serum albumin in vitro by DL-2-oxo-3-(2-mercaptoethyl)-5-phenyl-imidazolidine. Chicault M; Luu-Duc C; Boucherle A Arzneimittelforschung; 1984; 34(7):821-3. PubMed ID: 6541918 [TBL] [Abstract][Full Text] [Related]
2. Drug -- protein interactions in vitro. Effect of levamisole on human serum albumin. Chicault M; Luu Duc C; Boucherle A Arzneimittelforschung; 1982; 32(4):393-8. PubMed ID: 7201808 [TBL] [Abstract][Full Text] [Related]
3. Drug protein interactions. Chicault M; Luu Duc C; Boucherle A Arzneimittelforschung; 1981; 31(6):1015-20. PubMed ID: 7196231 [TBL] [Abstract][Full Text] [Related]
4. Levamisole inhibition of microsomal lipid peroxidation as related to its sulfhydryl metabolite dl-2-oxo-3-(2-mercaptoethyl)-5-phenylimadazolidine. Kumar KS; Dobbs CR; Weiss JF; Chirigos MA J Immunopharmacol; 1980; 2(1):73-83. PubMed ID: 7452005 [TBL] [Abstract][Full Text] [Related]
5. DL-2-Oxo-3-(2-mercaptoethyl)-5-phenylimidazolidine. A sulfhydryl metabolite of levamisole that interacts with microtubules. De Brabander M; Aerts F; Geuens G; van Ginckel R; van de Veire R; van Belle H Chem Biol Interact; 1978 Oct; 23(1):45-63. PubMed ID: 699190 [TBL] [Abstract][Full Text] [Related]
6. Drug-protein interactions. Comparative studies of levamisole and structural analogs or agents with immunomodulatory effect on the mechanism of protein aggregation. Chicault M; Luu-Duc C; Boucherle A Arzneimittelforschung; 1990 Jan; 40(1):55-7. PubMed ID: 2340000 [TBL] [Abstract][Full Text] [Related]
7. Drug-protein interactions. A study of levamisole-serum albumin complex by 1H-NMR spectroscopy. Chicault M; Luu-Duc C; Boucherle A; Nardin R Arzneimittelforschung; 1988 Sep; 38(9):1369-72. PubMed ID: 3223978 [TBL] [Abstract][Full Text] [Related]
8. The influence of a levamisole metabolite (DL-2-Oxo-3-[2-mercaptoethyl]-5-phenylimidazolidine) on carbon clearance in mice. Van Ginckel R; De Brabander M J Reticuloendothel Soc; 1979 Feb; 25(2):125-31. PubMed ID: 439095 [No Abstract] [Full Text] [Related]
9. Protective effect of levamisole and its sulfhydryl metabolite OMPI against cell death induced by glutathione depletion. De Brabander M; Van Belle H; Aerts F; Van De Veire R; Geuens G Int J Immunopharmacol; 1979; 1(2):93-100. PubMed ID: 551963 [No Abstract] [Full Text] [Related]
10. Prevention of peroxidase mediated inhibition of neutrophil motility and lymphocyte transformation by levamisole, OMPI, sodium aurothiomalate, indomethacin and tolmetin in vitro. Anderson R; Oosthuizen R; Grabow G Int J Immunopharmacol; 1981; 3(2):123-32. PubMed ID: 6266970 [TBL] [Abstract][Full Text] [Related]
11. Drug-protein interactions. On the protein-protein interaction induced by levamisole in vitro. A mechanism hypothesis. Chicault M; Luu Duc C; Boucherle A Arzneimittelforschung; 1988 Oct; 38(10):1387-9. PubMed ID: 3196377 [TBL] [Abstract][Full Text] [Related]
12. [Experimental analysis of embichin interaction with human serum albumin]. Luik AI; Novikova NV Farmakol Toksikol; 1980; 43(5):593-7. PubMed ID: 7449990 [TBL] [Abstract][Full Text] [Related]
13. Effect of D-penicillamine and levamisole on human lymphocytes in vitro. Pang T; Sivapatham C; Gong NC; Bosco J; Wang F Singapore Med J; 1982 Apr; 23(2):80-4. PubMed ID: 7135004 [No Abstract] [Full Text] [Related]
14. Unravelling the Structural Mechanism of Action of 5-methyl-5-[4-(4-oxo-3H-quinazolin-2-yl)phenyl]imidazolidine-2,4-dione in Dual-Targeting Tankyrase 1 and 2: A Novel Avenue in Cancer Therapy. Peters XQ; Agoni C; Soliman MES Cell Biochem Biophys; 2022 Sep; 80(3):505-518. PubMed ID: 35637423 [TBL] [Abstract][Full Text] [Related]
15. D-penicillamine-induced angiopathy in rats. The effect of high dose D-penicillamine treatment on aortic permeability to albumin and on the ultrastructure of the vessel. Jensen BA; Chemnitz J; Christensen BC; Junker P; Lorenzen I Acta Pathol Microbiol Immunol Scand A; 1983 Nov; 91(6):403-11. PubMed ID: 6666578 [TBL] [Abstract][Full Text] [Related]
16. Interaction of human serum albumin with the electrophilic metabolite 1-O-gemfibrozil-beta-D-glucuronide. Sallustio BC; Fairchild BA; Pannall PR Drug Metab Dispos; 1997 Jan; 25(1):55-60. PubMed ID: 9010630 [TBL] [Abstract][Full Text] [Related]
17. Evalution of capillary electrophoresis-frontal analysis for the study of low molecular weight drug-human serum albumin interactions. Østergaard J; Schou C; Larsen C; Heegaard NH Electrophoresis; 2002 Sep; 23(17):2842-53. PubMed ID: 12207290 [TBL] [Abstract][Full Text] [Related]
18. Comparative binding studies of anticonvulsant drugs to bovine serum albumin. Dal Pozzo A; Acquasaliente M; Tajana A Farmaco Sci; 1983 Aug; 38(8):609-18. PubMed ID: 6617856 [TBL] [Abstract][Full Text] [Related]
19. [Interaction of serum albumin with apoprotein E and very low density lipoproteins in human blood]. Dergunov AD; Vorotnikova IuIu Biokhimiia; 1993 Jun; 58(6):944-52. PubMed ID: 8364117 [TBL] [Abstract][Full Text] [Related]